International Journal of Pediatrics

Background: Patients with thalassemia major require regular monthly blood transfusion and excess iron from multiple blood transfusion deposits in different organs of the body, causing ... Read More Background: Patients with thalassemia major require regular monthly blood transfusion and excess iron from multiple blood transfusion deposits in different organs of the body, causing different organ damages. Cardiac iron overload is the main cause of death in patients with thalassemia major.Method: The aim of this study was to determine the effectiveness of Deferasirox (Nanojade) produced in Iran for the first time as a medicine in reducing iron overload of chronic blood transfusion in patients with Beta-thalassemia major. This is a pre-post quasi-experimental study that was performed on patients with thalassemia major involved in lifelong regular monthly blood transfusions. In this study, based on the existing protocols, injectable and dissolving iron chelating regimes were changed to a new generation of deferasirox oral tablets. To determine the effect of Nanojade, the mean level of the last three serum ferritin levels, before changing chelation, was compared with the serum ferritin levels after starting Nanojade. In the course of treatment, the possible side effects of Nanojade in various organs were monitored regularly.Results: The mean age of the patients was 16 years (ranging between 3 and 39 years). None of the patients had renal failure, elevated creatinine, or proteinuria with Nanojade. The most important side effect was elevated liver enzyme levels. The mean starting dose of Nanojade was 19.86± 5.78 mg/kg and the mean of the last dose was 23.41 ± 5.49 mg/kg. There was a statistically significant difference between the amount of ferritin at baseline with the serum ferritin of 6 and 18 months after chelation with Nanojade (P = 0.001).Conclusion: chelation with Nano Jade had less renal and hepatic side effects; and all of the patients had good compliance and significant reduction in the serum ferritin level in comparison to the results of other studies regarding the similar foreign deferasirox products.

Comparison of Quality of Life in Thalassemia Major Patients with Injectable and oral Iron Depletion

Majid Naderi; Ghasem Miri-Aliabad; Gholamreza Soleimani; Seyed Hosein Soleimanzadeh Mousavi; Saeideh Yaghoubi

Volume 9, Issue 11 , November 2021, , Pages 14747-14755

https://doi.org/10.22038/ijp.2021.54193.4285

Abstract

Background: One of the factors reducing the satisfaction and quality of life in thalassemia is the injection of iron-depleting drugs that always cause complications in these people. ... Read More

Prevalence of Restless Legs Syndrome (RLS) in children with thalassemia major in Ali Asghar Hospital in Zahedan, Iran

Majid Naderi; Zahra Ghiasi; Alireza Khosravi; Seyed hosein Soleimanzadeh Mousavi; Saeideh Yaghoubi

Volume 9, Issue 8 , August 2021, , Pages 14097-14104

https://doi.org/10.22038/ijp.2020.52325.4159

Abstract

Introduction: Thalassemia major is one of the most debilitating chronic and inherited diseases caused by impaired hemoglobin production. To improve the quality of life in the long-term ... Read More

The Comparison of Desfonak with Desferal in Patients with Beta Thalassemia Major: A Randomized Crossover Clinical Trial

Mohammad Reza Golpayegani; Nargece Soraya; Reza Akramipour; Mansour Rezaei

Volume 7, Issue 10 , October 2019, , Pages 10195-10204

https://doi.org/10.22038/ijp.2019.41060.3459

Abstract

Background Beta thalassemia (β-thalassemia) is one of the most common genetic disorders that reduces the amount of specific chain production in hemoglobin. The aim of this study ... Read More

Health-Related Quality of Life in Iranian Patients with Thalassemia Major: A Systematic Review and Meta-Analysis

Mitra Goli; Shahin Salarvand; Fazel Dehvan; Houshyar Ghafouri; Sahar Dalvand; Reza Ghanei Gheshlagh; Amir Vahedian-azimi

Volume 6, Issue 11 , November 2018, , Pages 8483-8494

https://doi.org/10.22038/ijp.2018.32565.2869

Abstract

Background: Thalassemia is the most common genetic disorder in Iran. High treatment costs, the use of iron chelators, comorbidities and periodic visits affect the quality of life in ... Read More

A Comparison of Quality of Life between Adolescences with Beta Thalassemia Major and their Healthy Peers

Shahram Baraz; Mojtaba Miladinia; Elham Mosavinouri

Volume 4, Issue 1 , January 2016, , Pages 1195-1204

https://doi.org/10.22038/ijp.2016.6228

Abstract

Background The chronic genetic blood disorder, thalassemia, affects Quality of life (QOL) negatively. Regarding this, if adolescences with thalassemia are treated well, they will grow ... Read More

Spurious Hyperleukocytosis

Amitabh singh; Anirban Mandal; Bhavika Rishi; Puneet Sahi

Volume 3, Issue 4.2 , August 2015, , Pages 799-800

https://doi.org/10.22038/ijp.2015.4512

Abstract

Hyperleukocytosis is an oncological emergency but is extremely rare in non-malignant conditions. Nucleated RBCs give rise to spuriously high total leucocyte count and cause clinical ... Read More

International Journal of Pediatrics

Articles in Press

Current Issue

Volume 11 (2023)

Volume 10 (2022)

Volume 9 (2021)

Volume 8 (2020)

Volume 7 (2019)

Volume 6 (2018)

Volume 5 (2017)

Volume 4 (2016)

Volume 3 (2015)

Volume 2 (2014)

Volume 1 (2013)

Keywords = Thalassemia Major

Advances in Iron Chelation Therapy: Towards A New Oral Formulation

Abstract

Comparison of Quality of Life in Thalassemia Major Patients with Injectable and oral Iron Depletion

Abstract

Prevalence of Restless Legs Syndrome (RLS) in children with thalassemia major in Ali Asghar Hospital in Zahedan, Iran

Abstract

The Comparison of Desfonak with Desferal in Patients with Beta Thalassemia Major: A Randomized Crossover Clinical Trial

Abstract

Health-Related Quality of Life in Iranian Patients with Thalassemia Major: A Systematic Review and Meta-Analysis

Abstract

A Comparison of Quality of Life between Adolescences with Beta Thalassemia Major and their Healthy Peers

Abstract

Spurious Hyperleukocytosis

Abstract